I'm LongbridgeAI, I can summarize articles.Ginkgo Bioworks partnered with Eli Lilly’s TuneLab to provide AI-driven drug discovery lab data. Ginkgo Datapoints will conduct small-molecule ADME testing and antibody developability screening, generating standardized ML-ready datasets. This collaboration aims to accelerate the design-to-lab validation cycle, allowing TuneLab participants to access additional platform model benefits by submitting these results.
- Ginkgo Bioworks struck an agreement with Lilly’s TuneLab platform to provide lab data generation services for AI-driven drug discovery. * Ginkgo Datapoints will run small-molecule ADME testing plus antibody developability screening for TuneLab participants. * Standardized assays aim to feed ML-ready datasets into TuneLab models, tightening the design-to-lab validation cycle. * TuneLab companies can submit Datapoints-generated results to access additional platform model benefits. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ginkgo Bioworks Holdings Inc. published the original content used to generate this news brief on September 16, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here